Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

October 31, 2031

Conditions
High Grade Glioma
Interventions
BIOLOGICAL

NK cells

"The universal donor TGFβi NK cells will be cryopreserved until they are delivered bedside for infusion. The trained staff will thaw the product by the bedside. The administration of the cells will be done via an Ommaya intra-cavitary/a programable ventriculoperitoneal (VP) shunt.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya/VP shunt in approximately 3 milliliters over approximately 2-5 minutes; followed by 1.5-2 milliliter preservative-free normal saline flush over approximately 1 minute."

Trial Locations (1)

43205

RECRUITING

Nationwide Children's Hospital, Columbus

All Listed Sponsors
lead

Nationwide Children's Hospital

OTHER